Free tool
FAERS Monitor: Polivy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761121 or its brand name (Polivy, Polatuzumab Vedotin-Piiq). Reports on generic versions are filed under their own applications.
Reports
10,202
Serious
9,659
95% of reports
Hospitalization
2,696
Death reported
2,154
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression2,064
- off label use1,398
- death801
- neutropenia642
- anaemia577
- covid-19549
- febrile neutropenia549
- cytokine release syndrome542
- pyrexia531
- drug ineffective503
- platelet count decreased434
- diffuse large b-cell lymphoma428
- pneumonia422
- neutrophil count decreased421
- blood lactate dehydrogenase increased419
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 8 |
| 2016 | 35 |
| 2017 | 21 |
| 2018 | 32 |
| 2019 | 253 |
| 2020 | 467 |
| 2021 | 719 |
| 2022 | 1,665 |
| 2023 | 2,266 |
| 2024 | 1,733 |
| 2025 | 1,550 |
| 2026 | 1,449 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,957 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diffuse large b-cell lymphomaSignal | 428 | 121.2 | 110.1 | 48,089 |
| cytokine release syndromeSignal | 542 | 57.2 | 52.7 | 29,106 |
| blood lactate dehydrogenase increasedSignal | 419 | 55.9 | 50.9 | 21,975 |
| disease progressionSignal | 2,064 | 36.6 | 35.2 | 70,552 |
| neutrophil count decreasedSignal | 421 | 21.5 | 19.6 | 8,143 |
| febrile neutropeniaSignal | 549 | 17.2 | 15.8 | 8,316 |
| neutropeniaSignal | 642 | 9.8 | 9.1 | 5,058 |
| platelet count decreasedSignal | 434 | 8.4 | 7.7 | 2,835 |
| covid-19Signal | 549 | 6.5 | 6.0 | 2,546 |
| anaemiaSignal | 577 | 6.3 | 5.8 | 2,557 |
| off label useSignal | 1,398 | 3.3 | 3.1 | 2,326 |
| pyrexiaSignal | 531 | 3.2 | 2.9 | 797 |
| pneumoniaSignal | 422 | 2.7 | 2.4 | 453 |
| death | 801 | 1.9 | 1.8 | 365 |
| drug ineffective | 503 | 0.8 | 0.7 | 31 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.